Cellular immunotherapy harnesses the body's own immune system to fight cancer by using engineered T cells, macrophages, or natural killer (NK) cells. Compared to chimeric antigen receptor T (CAR-T) cells that are commonly used to treat hematological malignancies, CAR-NK cells have shown remarkable therapeutic effectiveness while exhibiting enhanced safety, reduced risk of graft-versus-host disease, fewer side effects, and amplified antitumor efficacy. Preclinical trials have unveiled the high potential of adoptive CAR-NK cell therapy to curtail or even eliminate both hematological malignancies and solid tumors in animal models. We brought forth herein the design principle of CAR-NK cells, highlighted the latest progress in the preclinical testing and clinical trials of CAR-NK cells, briefly delved into discussed major roadblocks in CAR-NK therapy, and discussed potential solutions to surmount these challenges. Given the accelerated progress in both basic and translational studies on immune cell engineering, CAR-NK cell therapy promises to become a serious contender and important addition to the next-generation cell-based immunotherapy.

cancer;CAR-NK immunotherapy;chimeric antigen receptor (CAR);natural killer (NK) cells

Liu Siyao;Nguyen Kaycee;Park Dongyong;Wong Nelson;Wang Anson;Zhou Yubin

Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA;Department of Translational Medical Sciences, School of Medicine, Texas A&

慢性疾病与转化医学（英文）

[1]Liu Siyao;Nguyen Kaycee;Park Dongyong;Wong Nelson;Wang Anson;Zhou Yubin-.Harnessing natural killer cells to develop next-generation cellular immunotherapy)[J].慢性疾病与转化医学（英文）,2022(04):245-255

harnesses,contender

Harnessing,natural,killer,cells,develop,next,generation,cellular,immunotherapy,Cellular,body,immune,system,fight,cancer,by,using,engineered,macrophages,NK,Compared,chimeric,antigen,receptor,CAR,that,commonly,used,treat,hematological,malignancies,have,shown,remarkable,therapeutic,effectiveness,while,exhibiting,enhanced,safety,reduced,risk,graft,versus,host,disease,fewer,side,effects,amplified,antitumor,efficacy,Preclinical,trials,unveiled,potential,adoptive,curtail,even,eliminate,both,solid,tumors,animal,models,We,brought,forth,herein,design,principle,highlighted,latest,progress,preclinical,testing,briefly,delved,into,discussed,major,roadblocks,solutions,surmount,these,challenges,Given,accelerated,basic,translational,studies,engineering,promises,become,serious,important,addition

0.597273